LDX
data caveat$97M—
Lumos Diagnostics
Diagnostics · Infectious disease
Point-of-care diagnostics company. FebriDx rapid test differentiates bacterial vs viral acute respiratory infections. Pediatric validation study recruiting.
Data HealthTrials1 of 1 active · stale enrollment
No cash data on fileFigures from ASX filings · not financial advice
[ VITALS ]
Cash on Hand
—
Runway
—Market Cap
$97M
Burn Rate
—
Shares Outstanding
923M
Pipeline Assets
1
Latest Insightprice-sensitive announcements & broker notes
Price-sensitiveOther18 May 2026
FebriDx U.S. Rollout and Reimbursement Update - Amended
Lumos Diagnostics reports encouraging early progress on FebriDx® U.S. commercialisation following FDA CLIA waiver clearance. Over 90% of submitted reimbursement claims are being paid at rates above the Medicare fee schedule benchmark of US$41.38 per test, with FebriDx now in routine use across 44 WellStreet urgent care clinics and 8 additional pilot evaluations progressing with new urgent care operators ahead of the 2026/27 flu season.
3M Price
LDX.ASX$0.105-63.8% 3M
Low $0.105High $0.290
Pipeline Assets (1)
Discovery
Preclinical
Ph 1
Ph 1/2
Ph 2
Ph 2/3
Ph 3
NDA
Approved
Capital Raises & Buybacks
12mo dilution 1.0%12mo $2M1 raise
Current shares outstanding: 923M
SPP
2026-04-10spp
$2.0M
Other ticker dataInsider activity, holders, grants, publications
expand ›
Insider activity, holders, grants, publications
Director Transactions
5 transactionsLast 90dNet Buy
Buys3+3 vs prior
Sells0
Buy Value$89k
warning2 directors bought within 30 days (04-23 – 05-01) — $89k total
PERFORMANCE RIGHTSDOUG WARDopen_in_new
Catalysts (9)· 4 upcoming · 5 past
ExpectedremoveMed30 Sept 2026
Expectedarrow_upwardHigh31 Mar 2027
FebriDx paediatric FDA 510(k) submission
UpcomingExpectedHigh
Track RecordDelivery Consistency Index
expand ›
Delivery Consistency Index
Historical delivery and spending consistency. Data is limited for recently added companies.
Delivery Consistency Index
Delivery
–Insufficient data
1/3 data points needed
Timeline adherence · phase-adjusted tolerance · recency-weighted · min 3 catalysts
Capital discipline
–Insufficient data
0/2 data points needed
Burn rate stability · stage-adjusted thresholds · runway trend · R&D focus
Hit 1 of 1 guided dates· rolling 2yr(limited sample)· of 9 tracked
Completed catalysts
✓FebriDx commercial rollout across WellStreet urgent care clinics— FebriDx commercial rollout across WellStreet urgent care clinics is progressing as expected, with the product now in routine use across 44 WellStreet urgent care clinics and demonstrating strong reimbursement performance with over 90% of claims paid above Medicare benchmark rates.
500d early
Outcome quality (positive/negative readouts) reflects the science, not execution — shown above but excluded from the score.
These metrics reflect historical operational data only. They are not predictive of future performance, do not constitute investment advice, and should not be used as the basis for any investment decision.
Clinical Trials(3)
1 activeClinicalTrials.gov ↗
RecruitingOBSERVATIONALEnrollment stale · 244d
FebriDx
FebriDx® Pediatric Validation Study
Acute Respiratory Infections (ARIs)
2 Years – 11 Years
Primary endpoint Performance of the FebriDx® test
ENROL800
no manual snapshots — enter via record_enrollment.py
Announcements(20)
article
OtherPSauto_awesome
FebriDx U.S. Rollout and Reimbursement Update - Amended18 May 2026
expand_more377KB